Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non-viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.
Authors
- Yuichi Yamazaki (ORCID: https://orcid.org/0000-0002-8633-2983)
- Hiroki Tojima (ORCID: https://orcid.org/0000-0002-1646-2344)
- Takeshi Hatanaka (ORCID: https://orcid.org/0000-0003-3656-285X)
- Hisako Arai
- Keisuke Iizuka
- Satoshi Takakusagi (ORCID: https://orcid.org/0000-0002-4366-1699)
- Takayoshi Suga (ORCID: https://orcid.org/0000-0001-8417-1461)
- Toru Fukuchi
- Atsushi Naganuma (ORCID: https://orcid.org/0000-0003-0663-0102)
- Toshio Uraoka (ORCID: https://orcid.org/0000-0002-4425-4331)
- Daisuke Takizawa (ORCID: https://orcid.org/0000-0002-2004-8285)
- Satoru Kakizaki (ORCID: https://orcid.org/0000-0003-0224-7093)
- Takashi Ueno (ORCID: https://orcid.org/0000-0003-4054-9084)
- Shuichi Saito
Institutions
- Gunma University (JP)
- Maebashi Red Cross Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Sapporo Kosei General Hospital (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
- Isesaki Fukushima Hospital (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1002/jgh3.70081
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00